AngioDynamics (NASDAQ:ANGO) Reaches New 1-Year High – Time to Buy?

AngioDynamics, Inc. (NASDAQ:ANGO) reached a new 52-week high on Wednesday . The stock traded as high as $16.25 and last traded at $16.2160, with a volume of 12218 shares trading hands. The stock had previously closed at $15.82.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ANGO. Canaccord Genuity Group upped their price target on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. HC Wainwright raised their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Price Performance

The stock has a market capitalization of $653.84 million, a price-to-earnings ratio of -18.18 and a beta of 0.33. The stock’s 50 day simple moving average is $13.89 and its 200-day simple moving average is $12.03.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities research analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. The trade was a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 6.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ANGO. Farther Finance Advisors LLC boosted its stake in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of AngioDynamics during the fourth quarter worth about $27,000. State of Wyoming bought a new position in shares of AngioDynamics during the 2nd quarter worth approximately $31,000. Legal & General Group Plc bought a new position in AngioDynamics in the second quarter valued at $45,000. Finally, Russell Investments Group Ltd. increased its position in shares of AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.